Persistence to medical treatment of osteoporosis in women at three different clinical settings - A historical cohort study

被引:9
作者
Nielsen, Dorthe S. [1 ,2 ]
Langdahl, Bente L. [3 ]
Sorensen, Ole H. [4 ]
Sorensen, Henrik A. [4 ]
Brixen, Kim T. [2 ]
机构
[1] Odense Univ Hosp, Dept Endocrinol, DK-5000 Odense C, Denmark
[2] Univ So Denmark, Odense, Denmark
[3] Aarhus Univ Hosp, DK-8000 Aarhus, Denmark
[4] Osteoporosis Clin Hellerup, Copenhagen, Denmark
关键词
Information; medical treatment; osteoporosis; persistence; women's health; POSTMENOPAUSAL WOMEN; VERTEBRAL FRACTURES; RANDOMIZED-TRIAL; TREATMENT ADHERENCE; DRUG-THERAPY; PREVENTION; RATES; RISK; BONE; DENSITY;
D O I
10.1177/1403494810371243
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Purpose: This study was undertaken to assess persistence with bisphosphonates and raloxifene and to identify determinants of adherence (patient age, level of information, educational status, etc.) among women with osteoporosis in three different clinical settings in Denmark. Methods: We compared persistence to therapy in three historical cohorts of women diagnosed with osteoporosis starting therapy between January 1999 and January 2004. The study comprised 878 patients treated and followed at Odense University Hospital, 285 patients diagnosed and followed at the Hellerup Osteoporosis Clinic (private practice), and 343 patients diagnosed at Aarhus University Hospital and followed by the referring general practitioner. Data on persistence and possible confounders were collected using a mailed questionnaire. Reminders were issued after 1-2 months to non-respondents. Results: Persistence at 2 years as estimated from Kaplan-Meyer analysis was 0.87, 0.84 and 0.88 in the three cohorts, respectively. There were no significant differences between the clinics. Level of persistence was not related to patient assessment of the adequacy of the clinical information provided by the prescribing doctor, presence of prior fractures or a family history of osteoporosis. However, patients who read the information leaflet on their osteoporosis medication tended to be more persistent with treatment (p<0.09). Conclusions: Women's persistence with bisphosphonates and raloxifene was surprisingly high and similar between treating centres. This may be due to a high level of public information available on osteoporosis in Denmark.
引用
收藏
页码:502 / 507
页数:6
相关论文
共 29 条
[1]   Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].
Black, DM ;
Cummings, SR ;
Karpf, DB ;
Cauley, JA ;
Thompson, DE ;
Nevitt, MC ;
Bauer, DC ;
Genant, HK ;
Haskell, WL ;
Marcus, R ;
Ott, SM ;
Torner, JC ;
Quandt, SA ;
Reiss, TF ;
Ensrud, KE .
LANCET, 1996, 348 (9041) :1535-1541
[2]   The impact of compliance with osteoporosis therapy on fracture rates in actual practice [J].
Caro, JJ ;
Ishak, KJ ;
Huybrechts, KF ;
Raggio, G ;
Naujoks, C .
OSTEOPOROSIS INTERNATIONAL, 2004, 15 (12) :1003-1008
[3]   EFFECT OF CALCIUM AND CHOLECALCIFEROL TREATMENT FOR 3 YEARS ON HIP-FRACTURES IN ELDERLY WOMEN [J].
CHAPUY, MC ;
ARLOT, ME ;
DELMAS, PD ;
MEUNIER, PJ .
BRITISH MEDICAL JOURNAL, 1994, 308 (6936) :1081-1082
[4]   The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: A randomized controlled [J].
Clowes, JA ;
Peel, NFA ;
Eastell, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (03) :1117-1123
[5]   Telephone Counseling to improve osteoporosis treatment adherence: An effectiveness study in community practice settings [J].
Cook, Paul F. ;
Emiliozzi, Suzie ;
McCabe, Mishcha M. .
AMERICAN JOURNAL OF MEDICAL QUALITY, 2007, 22 (06) :445-456
[6]  
Cortet Bernard, 2006, Joint Bone Spine, V73, pe1, DOI 10.1016/j.jbspin.2006.02.006
[7]   A systematic review of persistence and compliance with bisphosphonates for osteoporosis [J].
Cramer, J. A. ;
Gold, D. T. ;
Silverman, S. L. ;
Lewiecki, E. M. .
OSTEOPOROSIS INTERNATIONAL, 2007, 18 (08) :1023-1031
[8]   Effect of calcium and vitamin D supplementation on bone, density in men and women 65 years of age or older [J].
DawsonHughes, B ;
Harris, SS ;
Krall, EA ;
Dallal, GE .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (10) :670-676
[9]   Study subjects and ordinary patients [J].
Dowd, R ;
Recker, RR ;
Heaney, RP .
OSTEOPOROSIS INTERNATIONAL, 2000, 11 (06) :533-536
[10]   Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene -: Results from a 3-year randomized clinical trial [J].
Ettinger, B ;
Black, DM ;
Mitlak, BH ;
Knickerbocker, RK ;
Nickelsen, T ;
Genant, HK ;
Christiansen, C ;
Delmas, PD ;
Zanchetta, JR ;
Stakkestad, J ;
Glüer, CC ;
Krueger, K ;
Cohen, FJ ;
Eckert, S ;
Ensrud, KE ;
Avioli, LV ;
Lips, P ;
Cummings, SR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (07) :637-645